| Index | — | P/E | — | EPS (ttm) | -2.24 | Insider Own | 5.46% | Shs Outstand | 141.25M | Perf Week | 1.00% |
| Market Cap | 8.41B | Forward P/E | — | EPS next Y | -2.81 | Insider Trans | -0.21% | Shs Float | 122.45M | Perf Month | -7.20% |
| Enterprise Value | 7.68B | PEG | — | EPS next Q | -1.52 | Short Float | 8.95% | Perf Quarter | -33.51% | ||
| Income | -320.00M | P/S | 12.58 | EPS this Y | — | Short Ratio | 5.79 | Perf Half Y | -22.02% | ||
| Sales | 669.00M | P/B | 18.06 | EPS next Y | — | ROA | -15.15% | Short Interest | 10.96M | Perf YTD | -10.27% |
| Book/sh | 3.30 | P/C | 5.25 | EPS next 5Y | — | ROE | -60.54% | 52W High | 95.49 -37.62% | Perf Year | 40.79% |
| Cash/sh | 11.34 | P/FCF | — | EPS past 3/5Y | — | ROIC | -12.12% | 52W Low | 37.06 60.74% | Perf 3Y | 144.14% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 50.54% 56.61% | Gross Margin | — | Volatility | 3.76% 3.77% | Perf 5Y | -9.54% |
| Dividend TTM | — | EV/Sales | 11.47 | EPS Y/Y TTM | — | Oper. Margin | -33.82% | ATR (14) | 2.46 | Perf 10Y | 789.10% |
| Dividend Ex-Date | — | Quick Ratio | 5.90 | Sales Y/Y TTM | 16.55% | Profit Margin | -47.79% | RSI (14) | 39.93 | Recom | 2.27 |
| Dividend Gr. 3/5Y | — | Current Ratio | 5.90 | EPS Q/Q | -7.94% | SMA20 | 0.31% | Beta | 1.33 | Target Price | 101.56 |
| Payout | — | Debt/Eq | 1.85 | Sales Q/Q | 167.86% | SMA50 | -13.97% | Rel Volume | 0.76 | Prev Close | 59.90 |
| Employees | 711 | LT Debt/Eq | 1.77 | Earnings | Nov 24 | SMA200 | -16.92% | Avg Volume | 1.72M | Price | 59.57 |
| IPO Date | Dec 16, 1993 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -6.53% — | Net Debt/EBITDA | — | Volume | 1,306,402 | Change | -0.55% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-15-26 | Reiterated | UBS | $110 → $109 | |
| Sep-24-26 | Resumed | Goldman Sachs | Neutral | $31 → $74 |
| Aug-31-26 | Reiterated | RBC Capital | Outperform | $80 → $100 |
| Aug-06-26 | Reiterated | HC Wainwright & Co. | Buy | $115 → $120 |
| Aug-05-26 | Reiterated | Stifel Nicolaus | $98 → $104 | |
| Jul-27-26 | Reiterated | HC Wainwright & Co. | Buy | $100 → $115 |
| Jul-23-26 | Reiterated | Morgan Stanley | Overweight | $100 → $120 |
| Jul-23-26 | Reiterated | Piper Sandler | Overweight | $110 → $126 |
| Jul-22-26 | Reiterated | Chardan Capital | Buy | $90 → $115 |
| Jul-13-26 | Initiated | Stifel | Buy | $98 |
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 9/30/2025 | FY 2024 9/30/2024 | FY 2023 9/30/2023 | FY 2022 9/30/2022 | FY 2021 9/30/2021 | FY 2020 9/30/2020 | FY 2019 9/30/2019 | FY 2018 9/30/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 669 | 829 | 4 | 241 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 19 | 12 | — | — | — | — | — | |
| Gross Profit | 669 | 829 | -15 | 228 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 171 | 122 | 97 | 91 | — | — | — | — | — | |
| Research and Development | 723 | 607 | 489 | 342 | — | — | — | — | — | |
| Other Operating Expense | 1 | 2 | 0 | 0 | — | — | — | — | — | |
| Operating Income | -226 | 98 | -601 | -205 | — | — | — | — | — | |
| Interest Expense | 94 | 89 | 32 | 18 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 68 | 43 | 21 | 17 | — | — | — | — | — | |
| Net Income Before Taxes | -253 | 52 | -612 | -206 | — | — | — | — | — | |
| Income Taxes | 20 | 21 | -3 | 3 | — | — | — | — | — | |
| Consolidated Net Income | -320 | -2 | -599 | -205 | — | — | — | — | — | |
| Net Income From Continuing Operations | -273 | 30 | -610 | -209 | — | — | — | — | — | |
| Net Income | -320 | -2 | -599 | -205 | — | — | — | — | — | |
| EPS (Recurring) | -2.24 | -0.01 | -5.00 | -1.92 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -2.24 | -0.01 | -5.00 | -1.92 | — | — | — | — | — | |
| EPS (Diluted) | -2.24 | -0.01 | -5.00 | -1.92 | — | — | — | — | — | |
| EBITDA | -134 | 165 | -562 | -176 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 12.73 | 5.57 | 581.10 | 11.93 | — | — | — | — | — | |
| Gross Margin | 100.00 | 100.00 | -375.00 | 94.61 | — | — | — | — | — | |
| Operating Margin | -33.78 | 11.82 | -15,025.00 | -85.06 | — | — | — | — | — | |
| Net Margin | -47.83 | -0.24 | -14,975.00 | -85.06 | — | — | — | — | — | |
| Shares Outstanding | 143 | 134 | 120 | 107 | — | — | — | — | — | |
| Market Capitalization | 8,519 | 4,622 | 2,324 | 2,875 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| OLUKOTUN ADEOYE Y | Director | Aug 18 '26 | Sale | 86.96 | 2,000 | 173,920 | 31,600 | Aug 20 |
| PERRY MICHAEL S | Director | Aug 18 '26 | Sale | 87.30 | 11,600 | 1,012,680 | 111,459 | Aug 20 |
| Lu Hongbo | Director | May 12 '26 | Sale | 76.88 | 2,970 | 228,334 | 52,012 | May 14 |
| Hamilton James C | Chief Medical Officer | Apr 23 '26 | Sale | 75.00 | 10,000 | 750,000 | 226,958 | Apr 24 |
| Apel Daniel Joseph | Chief Financial Officer | Apr 22 '26 | Sale | 71.35 | 13,095 | 934,286 | 162,905 | Apr 24 |
| Hamilton James C | Chief Medical Officer | Mar 05 '26 | Sale | 64.19 | 10,000 | 641,900 | 236,958 | Mar 09 |
| Hamilton James C | Chief Medical Officer | Jan 05 '26 | Sale | 63.11 | 40,164 | 2,534,661 | 171,958 | Jan 05 |
| O'Brien Patrick | COO | Jan 05 '26 | Sale | 63.11 | 49,493 | 3,123,349 | 474,908 | Jan 05 |
| Anzalone Christopher Richard | Chief Executive Officer | Jan 02 '26 | Sale | 66.10 | 13,187 | 871,703 | 3,792,739 | Jan 05 |
| Anzalone Christopher Richard | Chief Executive Officer | Dec 29 '25 | Option Exercise | 6.15 | 51,726 | 318,115 | 3,857,652 | Dec 30 |
| Anzalone Christopher Richard | Chief Executive Officer | Dec 29 '25 | Sale | 69.13 | 51,726 | 3,575,575 | 3,805,926 | Dec 30 |
| Ferrari Mauro | Director | Dec 26 '25 | Sale | 70.00 | 7,530 | 527,100 | 69,053 | Dec 30 |
| Anzalone Christopher Richard | Chief Executive Officer | Dec 22 '25 | Sale | 68.44 | 12,586 | 861,340 | 3,805,926 | Dec 23 |
| Anzalone Christopher Richard | Chief Executive Officer | Dec 19 '25 | Sale | 67.66 | 13,445 | 909,682 | 3,818,512 | Dec 23 |
| Waddill William D. | Director | Dec 19 '25 | Sale | 67.65 | 8,367 | 566,039 | 56,563 | Dec 23 |